

P.E.I. Pharmacare

Pharmacists' Bulletin**Issue (12-2)****(February 6, 2012)****NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY**

Product (Generic Name)	Product (Brand Name)	Strength	Dosage Form	DIN	MFR
------------------------	----------------------	----------	-------------	-----	-----

No new products have been added to the PEI Pharmacare Formulary this month.

NON-INSURED PRODUCTS

The following product(s) were recently reviewed by the Canadian Expert Drug Advisory Committee (CEDAC), the Atlantic Expert Advisory Committee (AEAC), or the pan-Canadian Oncology Drug Review (p-CODR) process and there was a "DO NOT LIST" recommendation for provincial public drug programs. As a result the following medications will **NOT** be listed as insured benefits under the PEI Pharmacare Formulary **NOR** will they be considered for coverage through the Special Authorization request process.

Oxycodone HCl	<u>OxyNEO</u>	All strengths	Extended Release Tablet		PFR
Indication	Relief of moderate to severe pain requiring the continuous use of an opioid analgesic preparation for several days or more				
AEAC Decision Highlights	The committee has recommended a comprehensive review of oxycodone for the treatment of pain compared to other drugs. The committee has also recommended that once OxyContin is discontinued, existing patients on OxyContin will be eligible to have OxyNEO covered until the review of oxycodone is completed.				

IMPORTANT NOTICES

Pharmacies should now be aware OxyContin has been discontinued by the manufacturer (Purdue Pharma) effective February 2012. Clients of PEI Pharmacare, who have current, active, approved Special Authorization Requests for OxyContin may contact their physician to have their prescription changed to OxyNEO (a long acting oxycodone product). Based on the recommendation by AEAC, and in the interest of continuing care to current clients who have been stabilized on OxyContin and have been receiving this drug through PEI Pharmacare, these clients will be eligible to receive OxyNEO (as of March 1, 2012) if their physician deems this appropriate. Clients changing to OxyNEO will require a new prescription from their physician, but will not need a new Special Authorization Request (their approved coverage for OxyContin will apply to OxyNEO).

Other than in the circumstance stated here, OxyNEO is not added to the PEI Pharmacare Formulary, and will not be considered under the Special Authorization process. Subsequent to the comprehensive oxycodone review being undertaken by the Atlantic Expert Advisory Committee, coverage of oxycodone products will be addressed at that time.